Abstract | OBJECTIVE: The efficacy of the mechanistic target of rapamycin inhibitor, sirolimus, was recently reported for patients more than 6 years of age by Kato et al. We evaluated the efficacy and safety of sirolimus in a 2-year-old patient with recurrent focal seizures with impaired consciousness after focal cortical dysplasia (FCD) type IIa resection. METHODS: The patient was a 2-year-old girl who had recurrent seizures after undergoing FCD resection at 4 months of age. The initial dose of sirolimus was 0.5 mg/day and was gradually increased using the trough blood concentration before oral administration as an index, and evaluation was performed at 92 weeks. RESULTS: The trough blood level of sirolimus was increased to 6.1 ng/mL and maintenance therapy was started at 40 weeks. Focal seizures with impairment of consciousness with tonic extension of the limbs decreased. No critically serious adverse events occurred. CONCLUSION:
Sirolimus was effective against epileptic seizures from FCD type II even for a child under 5 years of age. There were no critically serious adverse events and administration could be continued.
|
Authors | Hideaki Shiraishi, Tsuyoshi Teramoto, Saki Yokoshiki, Jun Tohyama, Yuki Ueda, Kiyoshi Egawa, Norihiro Sato, Atsushi Manabe, Mitsuhiro Kato |
Journal | Brain & development
(Brain Dev)
Vol. 45
Issue 6
Pg. 343-347
(Jun 2023)
ISSN: 1872-7131 [Electronic] Netherlands |
PMID | 36870920
(Publication Type: Case Reports)
|
Copyright | Copyright © 2023 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved. |
Chemical References |
|
Topics |
- Child
- Female
- Humans
- Child, Preschool
- Sirolimus
(therapeutic use, pharmacology)
- Focal Cortical Dysplasia
- Seizures
(drug therapy, etiology, surgery)
- Epilepsy
(drug therapy, etiology, surgery)
- Epilepsy, Generalized
- Malformations of Cortical Development
(complications, drug therapy)
- Magnetic Resonance Imaging
|